Dasatinib and docetaxel in advanced prostate cancer
Mené sur 1 522 patients atteints d'un cancer de la prostate de stade métastatique et résistant à la castration, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de dasatinib au docétaxel
In The Lancet Oncology , John C Araujo and colleagues 1 report the final results of the phase 3 READY trial of docetaxel with or without the Src family kinase (SFK) inhibitor dasatinib in patients with castration-resistant prostate cancer. The study is negative: dasatinib does not improve survival, or any of the typical measures of patient benefit, and now joins the long list of agents that fail to improve survival in men with castration-resistant prostate cancer when combined with docetaxel...
The Lancet Oncology , commentaire, 2012